|
Post by kc on May 31, 2017 19:30:21 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza.
|
|
|
Post by mnkdfann on May 31, 2017 19:40:55 GMT -5
|
|
|
Post by agedhippie on May 31, 2017 19:41:39 GMT -5
BIOMM's material facts filing (translation courtesy of Google)
BIOMM SA Public Company CNPJ / MF No. 04.752.991 / 0001-10 NIRE nº 31.300.016.510
FATO RELEVANTE
BIOMM SA ("Company" or "Biomm"), in compliance with the provisions of the Securities and Exchange Commission no. 358, of January 3, 2002, as amended, Shareholders and the market in general that on May 31, 2017, With MannKind Corporation an exclusive agreement for the supply, distribution and Product of Afrezza® (insulin human) Inhalation Powder , the name of which may be Be translated into Portuguese as Afrezza® Insulin Humana Inalável em Po, in Brazil ("Afrezza").
Under this agreement, the Company will be responsible for preparing and submitting the documents Necessary for the regulatory approval of Afrezza in Brazil, including the approval of the National Agency of Sanitary Surveillance (ANVISA) and, with regard to aspects pertinent to the Approval of the product, approval by the Market Regulation Medications (CMED). Once the approval of both regulatory bodies has been obtained, MannKind Corporation will produce and supply Afrezza to the Company, which will be responsible For the supply and distribution of the product in Brazil.
MannKind Corporation is a North American company that focuses on the Discovery, development and commercialization of therapeutic products for patients with Diseases such as diabetes.
The Company's management believes that, through the conclusion of said agreement, the Biomm, a pioneering Brazilian company in biotechnology and in the production and Insulin in the country, it will be able to leverage its current portfolio of diabetes products, offering A new option to improve the quality of life of those who have the disease.
The Company will keep its shareholders and the market in general informed on the subject matters Of this relevant fact.
Belo Horizonte, May 31, 2017. Douglas de Carvalho Lopes Director of Investor Relation
|
|
|
Post by porkini on May 31, 2017 19:47:41 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza. Okay, so first, sorry I do not know how to make this simple for any/everyone here. - You can download financials here - ri.biomm.com/conteudo_pt.asp?idioma=0&conta=28&tipo=57017
- Go to translate.google.com/ and click the link under the box to "translate a document"
- Click "Choose File" and select the file you saved/downloaded
- Change drop down from "Detect language" to "Portuguese"
- Verify you have "English" selected on the right (if that is what you speak/read)
You will still have to do a currency conversion, but the financial looks much more readable.
Edit: and then after posting this, I see mnkdfann perhaps has a better mousetrap here - mnkd.proboards.com/post/109403
|
|
|
Post by kc on May 31, 2017 19:56:01 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. Perhaps BIOMM has also been buying shares? Their financials are in Portuguese so I can't read to determine what the financial strength of that company might be. .
|
|
|
Post by kc on May 31, 2017 19:57:19 GMT -5
The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza. Okay, so first, sorry I do not know how to make this simple for any/everyone here. - You can download financials here - ri.biomm.com/conteudo_pt.asp?idioma=0&conta=28&tipo=57017
- Go to translate.google.com/ and click the link under the box to "translate a document"
- Click "Choose File" and select the file you saved/downloaded
- Change drop down from "Detect language" to "Portuguese"
- Verify you have "English" selected on the right (if that is what you speak/read)
You will still have to do a currency conversion, but the financial looks much more readable.
Edit: and then after posting this, I see mnkdfann perhaps has a better mousetrap here - mnkd.proboards.com/post/109403
Yes I know about Google translate I was just too lazy to do it and wanted to go home for the day from the office
|
|
|
Post by porkini on May 31, 2017 19:58:04 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. Perhaps BIOMM has also been buying shares? Their financials are in Portuguese so I can't read to determine what the financial strength of that company might be. . Read my post just above - mnkd.proboards.com/post/109407/thread
|
|
|
Post by porkini on May 31, 2017 19:59:03 GMT -5
Okay, so first, sorry I do not know how to make this simple for any/everyone here. - You can download financials here - ri.biomm.com/conteudo_pt.asp?idioma=0&conta=28&tipo=57017
- Go to translate.google.com/ and click the link under the box to "translate a document"
- Click "Choose File" and select the file you saved/downloaded
- Change drop down from "Detect language" to "Portuguese"
- Verify you have "English" selected on the right (if that is what you speak/read)
You will still have to do a currency conversion, but the financial looks much more readable.
Edit: and then after posting this, I see mnkdfann perhaps has a better mousetrap here - mnkd.proboards.com/post/109403
Yes I know about Google translate I was just too lazy to do it and wanted to go home for the day from the office Haha - yeah, me too - outta here, have a good evening!
|
|
|
Post by factspls88 on May 31, 2017 20:02:16 GMT -5
Whoa just got home and checked AH. Awesome!
|
|
|
Post by falconquest on May 31, 2017 20:17:50 GMT -5
Glad to see some foreign market progress. It will be interesting to see how the market accepts Afrezza in Brazil compared to the U.S. My guess is it will be a much more rapid progression as long as people can afford it. So what will Mike do, allow the share price to move up and then float another offering? We need cash.
|
|
|
Post by boytroy88 on May 31, 2017 20:27:48 GMT -5
Glad to see some foreign market progress. It will be interesting to see how the market accepts Afrezza in Brazil compared to the U.S. My guess is it will be a much more rapid progression as long as people can afford it. So what will Mike do, allow the share price to move up and then float another offering? We need cash. Tinkerbell mentioned that Matt has three priorities that he was working on and it looks like they expect those to come to fruition by July 2017. I think they won't float anything till then. "TWO MORE, TWO MORE!!"
|
|
|
Post by mnholdem on May 31, 2017 20:35:33 GMT -5
What is especially exciting about this deal is that, unlike MannKind here in the USA, Biomm is known and has been respected by the Brazilian medical community for 40+ years. Because Biomm is so well known and were the #1 insulin manufacturer & distributor in Brazil (#4 globally) once they launch Afrezza, I believe you will see very rapid sales growth. They won't face the obstacles MannKind has had to overcome.
Great choice, MannKind!
|
|
|
Post by seanismorris on May 31, 2017 20:36:39 GMT -5
This could be a path to outsourcing Afrezza production to Brazil. I'd be concerned about outsourcing production to China (for example) because they don't respect Intellectual Property, but Brazil gets two thumbs up.
Lowering costs at MannKind remains a priority, but getting additional funding shouldn't be a problem. I doubt the deal in Brazil includes an upfront payment, so we're still looking at dilution before the year is out.
I wonder if Afrezza OTC is on the table for Brazil...
It's nice to see MannKind set up some nice PR for Mike starting his new position. It also explains the timing of Mat leaving.
|
|
|
Post by madog365 on May 31, 2017 20:56:25 GMT -5
This could be a path to outsourcing Afrezza production to Brazil. I'd be concerned about outsourcing production to China (for example) because they don't respect Intellectual Property, but Brazil gets two thumbs up. Lowering costs at MannKind remains a priority, but getting additional funding shouldn't be a problem. I doubt the deal in Brazil includes an upfront payment, so we're still looking at dilution before the year is out. I wonder if Afrezza OTC is on the table for Brazil... It's nice to see MannKind set up some nice PR for Mike starting his new position. It also explains the timing of Mat leaving. Brazilian listed pharmaceutical company Biomm Technology has announced plans to resume the manufacture of insulin in Brazil in a plant in Nova Lima, in the metropolitan region of Minas Gerais, with planned investment of R$330 million. It will be the country's sole production of insulin, after Danish multinational Novo Nordisk bought Biobrás, the company from which Biomm originated, and shut down it's factory in Montes Claros, also in the state of Minas Gerais. Biomm's new factory is expected to be ready by 2015, and generate R$118 million in revenue in the first year, R$217 million in the second and R$305 million in the third www.estadao.com.br/noticias/geral,biomm-investira-r-330-mi-em-fabrica-de-insulina-em-mg,949887 Biomm to invest R $ 330m in insulin factory in MGBiomm Technology, a Brazilian company specializing in biotechnology products, confirmed on Tuesday its intention to invest R $ 330 million in the construction of a plant for the production of human insulin and therapeutic proteins in Nova Lima, in the metropolitan region of Belo Horizonte. The unit is due to come on stream in 2015, with an estimated annual production of 20 million bottles of insulin. The product moved last year about US $ 14 billion and is estimated to be a 20% increase in demand until the year in which the Nova Lima unit is expected to start producing. Of the total investment in the plant, R $ 56 million will be financed by the Foundation for Research Support of the State of Minas Gerais (Fapemig) and the Minas Gerais Development Bank (BDMG), which still has R $ 29 million in capital Shareholder. According to Biomm, the project will generate 208 direct and 624 indirect jobs. The company, based in the capital of Minas Gerais, was created in 2001 by a spin-off of Biobrás, which was bought by the Danish company Novo Nordisk, one of the leaders in the world insulin market and already has a unit for manufacturing the product in Montes Claros, In the north of Minas.
|
|
|
Post by mnholdem on May 31, 2017 21:08:26 GMT -5
Perhaps some of our members will now appreciated the value of retaining and protecting your intellectual property. Biomm kept all of theirs before splitting the company, with the IP staying with Biomm even when Novo Nordisk acquired control of the other company. With Technosphere as the delivery system, Biomm may consider other drugs besides insulin. We've saying this for years. With a company like Biomm, today is just a small taste of the future. Good fortune all!
|
|